Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

34 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Comparison of Safety and Vector-Specific Immune Responses in Healthy and HIV-Infected Populations Vaccinated with MVA-B.
Couto E, Diaz-Brito V, Mothe B, Guardo AC, Fernandez I, Ugarte A, Etcheverry F, Gómez CE, Esteban M, Pich J, Arnaiz JA, López Bernaldo de Quirós JC, Brander C, Plana M, García F, Leal L. Couto E, et al. Among authors: guardo ac. Vaccines (Basel). 2019 Nov 7;7(4):178. doi: 10.3390/vaccines7040178. Vaccines (Basel). 2019. PMID: 31703287 Free PMC article.
The HIV/AIDS vaccine candidate MVA-B administered as a single immunogen in humans triggers robust, polyfunctional, and selective effector memory T cell responses to HIV-1 antigens.
Gómez CE, Nájera JL, Perdiguero B, García-Arriaza J, Sorzano CO, Jiménez V, González-Sanz R, Jiménez JL, Muñoz-Fernández MA, López Bernaldo de Quirós JC, Guardo AC, García F, Gatell JM, Plana M, Esteban M. Gómez CE, et al. Among authors: guardo ac. J Virol. 2011 Nov;85(21):11468-78. doi: 10.1128/JVI.05165-11. Epub 2011 Aug 24. J Virol. 2011. PMID: 21865377 Free PMC article. Clinical Trial.
Safety and immunogenicity of a modified pox vector-based HIV/AIDS vaccine candidate expressing Env, Gag, Pol and Nef proteins of HIV-1 subtype B (MVA-B) in healthy HIV-1-uninfected volunteers: A phase I clinical trial (RISVAC02).
García F, Bernaldo de Quirós JC, Gómez CE, Perdiguero B, Nájera JL, Jiménez V, García-Arriaza J, Guardo AC, Pérez I, Díaz-Brito V, Conde MS, González N, Alvarez A, Alcamí J, Jiménez JL, Pich J, Arnaiz JA, Maleno MJ, León A, Muñoz-Fernández MA, Liljeström P, Weber J, Pantaleo G, Gatell JM, Plana M, Esteban M. García F, et al. Among authors: guardo ac. Vaccine. 2011 Oct 26;29(46):8309-16. doi: 10.1016/j.vaccine.2011.08.098. Epub 2011 Sep 9. Vaccine. 2011. PMID: 21907749 Clinical Trial.
In vitro effects of the CCR5 inhibitor maraviroc on human T cell function.
Arberas H, Guardo AC, Bargalló ME, Maleno MJ, Calvo M, Blanco JL, García F, Gatell JM, Plana M. Arberas H, et al. Among authors: guardo ac. J Antimicrob Chemother. 2013 Mar;68(3):577-86. doi: 10.1093/jac/dks432. Epub 2012 Nov 14. J Antimicrob Chemother. 2013. PMID: 23152485
Differential microRNA expression profile between stimulated PBMCs from HIV-1 infected elite controllers and viremic progressors.
Egaña-Gorroño L, Escribà T, Boulanger N, Guardo AC, León A, Bargalló ME, Garcia F, Gatell JM, Plana M, Arnedo M; HIV Controllers Consortium of the AIDS Spanish Network. Egaña-Gorroño L, et al. Among authors: guardo ac. PLoS One. 2014 Sep 16;9(9):e106360. doi: 10.1371/journal.pone.0106360. eCollection 2014. PLoS One. 2014. PMID: 25225963 Free PMC article.
Protease inhibitor monotherapy is associated with a higher level of monocyte activation, bacterial translocation and inflammation.
Torres B, Guardo AC, Leal L, Leon A, Lucero C, Alvarez-Martinez MJ, Martinez MJ, Vila J, Martínez-Rebollar M, González-Cordón A, Gatell JM, Plana M, García F. Torres B, et al. Among authors: guardo ac. J Int AIDS Soc. 2014 Sep 29;17(1):19246. doi: 10.7448/IAS.17.1.19246. eCollection 2014. J Int AIDS Soc. 2014. PMID: 25280865 Free PMC article.
Safety and immunogenicity of a modified vaccinia Ankara-based HIV-1 vaccine (MVA-B) in HIV-1-infected patients alone or in combination with a drug to reactivate latent HIV-1.
Mothe B, Climent N, Plana M, Rosàs M, Jiménez JL, Muñoz-Fernández MÁ, Puertas MC, Carrillo J, Gonzalez N, León A, Pich J, Arnaiz JA, Gatell JM, Clotet B, Blanco J, Alcamí J, Martinez-Picado J, Alvarez-Fernández C, Sánchez-Palomino S, Guardo AC, Peña J, Benito JM, Rallón N, Gómez CE, Perdiguero B, García-Arriaza J, Esteban M, López Bernaldo de Quirós JC, Brander C, García F; RISVAC-03 Study Group. Mothe B, et al. Among authors: guardo ac. J Antimicrob Chemother. 2015;70(6):1833-42. doi: 10.1093/jac/dkv046. Epub 2015 Feb 26. J Antimicrob Chemother. 2015. PMID: 25724985 Clinical Trial.
Immune Reconstitution in Severely Immunosuppressed Antiretroviral-Naive HIV-1-Infected Patients Starting Efavirenz, Lopinavir-Ritonavir, or Atazanavir-Ritonavir Plus Tenofovir/Emtricitabine: Final 48-Week Results (The Advanz-3 Trial).
Miro JM, Manzardo C, Ferrer E, Loncà M, Guardo AC, Podzamczer D, Domingo P, Curran A, Clotet B, Cruceta A, Lozano F, Pérez I, Plana M, Gatell JM; Advanz-3 Study Group. Miro JM, et al. Among authors: guardo ac. J Acquir Immune Defic Syndr. 2015 Jun 1;69(2):206-15. doi: 10.1097/QAI.0000000000000567. J Acquir Immune Defic Syndr. 2015. PMID: 25831464 Clinical Trial.
34 results